Group 1 - The report indicates that there were no changes in the issued shares for both H-shares and A-shares of Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd. as of July 31, 2025 [1][2] - The total issued share capital remains at RMB 360,593,720, with 27,553,260 H-shares and 333,040,460 A-shares unchanged from the previous month [1][2] - The report confirms that there were no new shares issued or treasury shares transferred during the month [1][2] Group 2 - The report specifies that there are no applicable details regarding stock options, warrants, or convertible bonds for the company [1][2] - There were no changes in treasury shares for both H-shares and A-shares, with the total remaining at 0 for the month [2] - The report does not include any information related to Hong Kong depositary receipts [2][3]

Group I - The report details the changes in the registered capital of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. as of July 31, 2025, indicating no increase or decrease in the registered capital for the month [1]. - The total registered capital at the end of the month is RMB 2,670,429,325, with no changes reported from the previous month [1]. - The number of issued shares (excluding treasury shares) remains unchanged at 540,971,500 for the security code 02196 and 2,098,582,573 for the security code 600196 [1]. Group II - The report confirms that all securities issuance or treasury share transactions have been authorized by the board of directors and comply with applicable listing rules and regulations [2]. - It states that all necessary conditions for listing have been fulfilled, and all required documents have been filed with the relevant authorities [2]. - The report also confirms that all ownership documents related to the issuance, sale, or transfer of shares have been prepared and sent as required [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 加入國際多中心 III 期臨床試驗的申請已獲中國藥監局默示許可 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 董事會欣然公告，本集團用於治療前列腺癌的全球創新在研放射性核素偶聯藥物 「( RDC」) TLX591 (177Lu-rosopatamab tetraxetan)加入國際多中心 III 期臨床試驗的申請， 近日已獲得中華人民共和國國家藥品監督管理局(「中國藥監局」)默示許可，這是本集 團在核藥抗腫瘤診療領域的重要研發進展。本集團高度重視核藥產業全球化發展戰略， 積極推進創新核藥產品的全球化開發及註冊進程，並將持續深化本集團核藥產品管線的 全球化拓展。 該研究是一項前瞻性、隨機、對照、開放標籤、國際多中心的 III 期臨床試驗，擬在中 國、美國、澳大利亞、新西蘭及歐洲等全球多個國家和地區入組 500 余名患者，旨在評 估 TLX591 ...

Market Overview - The Hang Seng Index is facing resistance at 24,700 points, with a forecasted P/E ratio of 11 times over the next 12 months [2] - The index experienced fluctuations, reaching a high of 24,672 points before closing at 24,498 points, down 0.1% [5] Macro Focus - U.S. retail sales increased by 0.6% in June, exceeding expectations and reversing a two-month decline [3][8] - The unemployment rate for individuals aged 16 to 24 in mainland China decreased to 14.5%, marking a four-month decline [7] - The People's Bank of China conducted a reverse repurchase operation of 450.5 billion yuan, maintaining the interest rate at 1.4% [7] Company News - Luk Fook Holdings reported a 13% increase in overall retail value for the first quarter, reversing previous declines [9] - Federation Pharmaceutical is raising approximately 2.2 billion HKD through a share placement at a discount of 7.9% [9] - Ideal Auto has opened pre-orders for its i8 model, with expected prices starting from 350,000 yuan [9] - October Rice reported a projected net profit increase of at least 90% for the first half of the year [9] - Changjie Tong anticipates a profit of 31 to 37 million yuan for the first half of the year, driven by strong cloud service performance [9] Sector Insights - The biotechnology sector is expected to benefit from new measures supporting the high-quality development of innovative drugs [6] - The tourism sector is seeing an increase in cross-border traffic, indicating a potential rise in summer tourism [6] - Brokerage stocks are gaining traction as the Shanghai Composite Index surpasses 3,500 points, continuing the trend of A+H listings [6]

JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 關於加科思 （股份代號：1167） 自願公告 加科思完成泛KRAS抑制劑JAB-23E73 I/IIa期 臨床試驗在美國的首例患者給藥 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統稱「本集 團」）自願刊發，以告知本公司股東及潛在投資者有關本集團最新業務發展的資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司自主研發的泛KRAS抑制劑JAB- 23E73在美國完成I/IIa期臨床試驗首例患者給藥。目前該藥物在中國的劑量遞增研究也正 按計劃順利推進。 KRAS是最常導致致癌突變的基因之一，約23%-25%的癌症患者帶有KRAS突變，其在胰 腺癌（約90%）、結直腸癌（約40%）和非小細胞肺癌（約30%）中突變頻率尤為顯著。全球每 年新增約270 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 有關與大塚就HBM7020戰略合作的業務更新 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）按自 願基準作出，以知會本公司股東及潛在投資者有關本集團的最新業務更新。 和鉑醫藥控股有限公司 本公司董事會（「董事會」）欣然宣佈，本集團已與大塚製藥株式會社（「大塚」）訂立 全球戰略合作協議（「該協議」），以推進用於治療自身免疫性疾病的BCMAxCD3 雙特異性T細胞銜接器HBM7020。根據該協議，大塚獲授予在全球範圍內（不包 括大中華區，即中國大陸、香港、台灣及澳門）開發、製造及商業化HBM7020的 獨家授權。 根據該協議的條款，本公司有權獲得總計47百萬美元的首期及近期付款，並在實 現特定開發及商業化里程碑時，有權獲得高達623百萬美元的潛在里程碑付款， 以及未來淨銷 ...

Group 1: Individual Stock Recommendations - The report recommends buying shares of Lao Pu Gold (6181) at a current price of 914.00 HKD, with a short-term target price of 994.00 HKD, indicating a potential upside of 14.3%. The catalysts for this recommendation include strong same-store sales growth and the launch of a new product series expected to boost sales in the second half of 2025 [2][12] - The report also recommends buying shares of Kingsoft (3888) at a current price of 36.60 HKD, with a short-term target price of 41.30 HKD, indicating a potential upside of 15.4%. The catalysts include the upcoming launch of new games expected to drive revenue growth in the second half of 2025 [2][15] Group 2: Market Overview and Economic Indicators - The Hang Seng Index is currently facing resistance at the March high of 24,874 points, with recent financial policies from mainland China aimed at stabilizing the market. The market anticipates further policy measures to support economic growth [3][6] - The report highlights that the U.S. inflation rate is moderating, which has led to a slight increase in U.S. stock indices. The U.S. Producer Price Index (PPI) showed a mild increase of 0.1% month-on-month in May, indicating a stable inflation environment [4][16] Group 3: Industry Insights - The report notes that the traditional gold jewelry market in mainland China has experienced a compound annual growth rate (CAGR) of 65% from 2018 to 2023, with expectations for a CAGR of approximately 22% from 2023 to 2028 [12] - The report indicates that Kingsoft's gaming and office software revenue is expected to improve sequentially, with a projected CAGR of 13% for revenue and 22% for net profit from FY24 to FY27 [15]

Summary of Key Points Core Viewpoint - The report details the changes in issued shares and treasury shares of Lee's Pharmaceutical Holdings Limited, highlighting a decrease in the total issued shares from 307,052,417 to 299,807,117 between April 30, 2025, and May 14, 2025, due to share repurchases [2]. Group 1: Share Issuance and Changes - The total issued shares (excluding treasury shares) as of April 30, 2025, were 307,052,417 [2]. - As of May 14, 2025, the total issued shares decreased to 299,807,117, indicating a reduction of 7,245,300 shares [2]. - The report confirms that the changes in share capital have been authorized by the board and comply with applicable listing rules and regulations [3]. Group 2: Treasury Shares - The report does not indicate any changes in treasury shares, which remained at 604,293,313 as of both April 30, 2025, and May 14, 2025 [2]. - The company has not yet canceled the repurchased shares as of the reporting date [3]. Group 3: Compliance and Authorization - The report confirms compliance with all relevant listing rules, legal requirements, and regulatory provisions regarding the issuance and repurchase of shares [3]. - All necessary documentation and approvals related to the share transactions have been completed and filed as required [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 該產品在全球範圍內的註冊上市工作正順利推進。TLX591-CDx 於二零二一年十一月在 澳大利亞獲批上市，同年十二月在美國獲批上市；於二零二二年十月在加拿大獲批上市； 於二零二三年三月在美國批准擴展適應症，用於篩選可接受 PSMA 靶向放射性核素治 療的前列腺癌患者，並於二零二四年十月在澳大利亞、加拿大相繼批准擴展該適應症； 通過非集中審評程序，於二零二五年一月推薦在歐洲經濟區國家上市，同年二月在英國 獲批上市，並通過互認程序，相繼在丹麥、挪威、馬爾他、盧森堡、荷蘭、瑞典、法國、 芬蘭、愛爾蘭、捷克獲批上市；並於同年三月獲得巴西批准上市。該產品已在二零二四 年實現銷售額 7.83 億澳元（5.17 億美元）；二零二五年第一季度銷售額為 1.51 億美元， 同比增長約 35%。 該產品海外臨床研究方面，TLX591-CDx 於二零二二年二 ...

（股份代號：1167） 自願公告 SHP2抑制劑SITNEPROTAFIB聯用研究數據發表於學術期刊 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統稱「本集 團」）自願刊發，以告知本公司股東及潛在投資者有關本集團最新業務發展的資料。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） Sitneprotafib（JAB-3312）是一種高選擇性的SHP2抑制劑，具有同類最佳潛力。加科思目前 正在中國、美國和歐洲進行多項JAB-3312的臨床試驗，包括和KRAS G12C抑制劑glecirasib 等項目的聯合用藥試驗。與glecirasib聯合用藥的三期臨床試驗於2024年2月在中國國家藥 品監督管理局藥品評審中心獲批。 香港聯合交易所有限公 ...